Eribulin, trastuzumab, and pertuzumab as first-line therapy for patients with HER2-positive metastatic breast cancer: a phase II, multicenter, collaborative, open-label, single-arm clinical trial
Conclusions ETP therapy showed acceptable efficacy and safety and is a potential first-line therapy for patients with HER2-positive MBC.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research
More News: Alopecia | Brain | Breast Cancer | Cancer | Cancer & Oncology | Clinical Trials | Drugs & Pharmacology | HER2 | Herceptin | Investigational New Drugs | Liver | Neurology | Peripheral Neuropathy | Urology & Nephrology | Women